Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 12/8/2006


1.		Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV, Phase III				Treatment				Active				21 and under				Other				GPOH-NB2004 EU-20661, NCT00410631


2.		Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 75				Other				ADO-MM-PAL8 NCT00226473


3.		Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				16 to 75				Other				CGC05MK1002 NCT00188149

Last Modified: 5/18/2007 First Published: 7/1/2002


4.		Phase III Randomized Study of Bleomycin, Doxorubicin, Etoposide, Mechlorethamine, Vinblastine, Vincristine, and Prednisone (Stanford V) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Previously Untreated Advanced Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				BNLI-STANFORDV EU-20206, NCT00041210

Last Modified: 1/6/2009 First Published: 11/1/2002


5.		Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 60				Other				EORTC-20012 GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595


6.		A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				LX01-315 NCT00395070

First Published: 2/5/2007


7.		Phase III Randomized Study of Early Fludeoxglucose F 18 Positron Emission Tomography Scan-Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Previously Untreated Supradiaphragmatic Stage I or II Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				15 to 70				Other				EORTC-20051 GELA-H10, EUDRACT-2005-002765-37, NCT00433433

Last Modified: 6/19/2008 First Published: 2/5/2007


8.		Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic, Treatment				Active				Under 18				Other				EURONET-PHL-C1 EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10


9.		Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				AGENDA GM307, NCT00518895

Last Modified: 9/30/2008 First Published: 5/8/2008


10.		Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CRUK-2007-006064-30 2007-006064-30, CRUK-07/146, NCT00678327

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute